

This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims:

1-19. (canceled)

20. (currently amended) ~~The method of Claim 17~~ A method for imaging a pulmonary embolus comprising the steps of:

- a. localizing a radiolabelled compound at the pulmonary embolus;
- b. acquiring image slices representing the concentration of radioactivity within the radiolabelled pulmonary embolus;
- c. assembling the image slices into a three-dimensional matrix of data;
- d. scanning the three-dimensional matrix of data along an array of parallel lines to determine a maximum value along each line; and
- e. assigning the maximum value along each line to a pixel in a two-dimensional array, the position of the pixel corresponding to the position of the line in the array of parallel lines;

wherein the localization step comprises the step of localizing a compound of the formula (I), and pharmaceutically acceptable salts thereof, at the thrombus:



(I) ,

wherein,

Q is a glycoprotein IIb/IIIa binding compound;

DOCKET NO.: DM6993/BMS-0689
Application No.: 09/534,893
Office Action Dated: April 11, 2003

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**

d' is 1 - 20;

L_n is a linking group of formula:

M¹-[Y¹(CR⁵⁵R⁵⁶)f(Z¹)f'Y²]f-M²,

wherein:

M¹ is -[(CH₂)_gZ¹]_{g'}-(CR⁵⁵R⁵⁶)_{g''}-;

M² is -(CR⁵⁵R⁵⁶)_{g''}-[Z¹(CH₂)_g]_{g'}-;

g is independently 0-10;

g' is independently 0-1;

g'' is independently 0-10;

f is independently 0-10;

f' is independently 0-10;

f'' is independently 0-1;

Y^1 and Y^2 , are independently selected at each occurrence from: a bond, O, NR^{56} , $C=O$, $C(=O)O$, $OC(=O)O$, $C(=O)NH-$, $C=NR^{56}$, S, SO, SO_2 , SO_3 , $NHC(=O)$, $(NH)_2C(=O)$, and $(NH)_2C=S$;

Z^1 is independently selected at each occurrence from a C6-C14 saturated, partially saturated, or aromatic carbocyclic ring system, substituted with 0-4 R^{57} ; and a heterocyclic ring system, substituted with 0-4 R^{57} ;

R^{55} and R^{56} are independently selected at each occurrence from: hydrogen; C1-C10 alkyl substituted with 0-5 R^{57} ; and alkaryl wherein the aryl is substituted with 0-5 R^{57} ;

R^{57} is independently selected at each occurrence from the group: hydrogen, OH, NHR^{58} , $C(=O)R^{58}$, $OC(=O)R^{58}$, $OC(=O)OR^{58}$, $C(=O)OR^{58}$, $C(=O)NR^{58}$, $C\equiv N$, SR^{58} , SOR^{58} , SO_2R^{58} , $NHC(=O)R^{58}$, $NHC(=O)NHR^{58}$, $NHC(=S)NHR^{58}$; or, alternatively, when attached to an additional molecule Q, R^{57} is independently selected at each occurrence from the group: O, NR^{58} , $C=O$, $C(=O)O$, $OC(=O)O$, $C(=O)N-$, $C=NR^{58}$, S, SO, SO_2 , SO_3 , $NHC(=O)$, $(NH)_2C(=O)$, $(NH)_2C=S$; and,

R^{58} is independently selected at each occurrence from the group: hydrogen; C1-C6 alkyl; benzyl, and phenyl;

M_T is a transition metal radionuclide;

C_h is a radionuclide metal chelator or bonding unit bound to the transition metal radionuclide selected from the group consisting of: $R^{40}N=N^+=$, $R^{40}R^{41}N-N=$, $R^{40}N=$, or $R^{40}N=N(H)-$;

R^{40} is independently selected at each occurrence from the group: a bond to L_n , C1-C10 alkyl substituted with 0-3 R^{52} , aryl substituted with 0-3 R^{52} , cycloalkyl substituted with 0-3 R^{52} , heterocycle substituted with 0-3 R^{52} , heterocycloalkyl substituted with 0-3 R^{52} , aralkyl substituted with 0-3 R^{52} and alkaryl substituted with 0-3 R^{52} ;

R^{41} is independently selected from the group: hydrogen, aryl substituted with 0-3 R^{52} , C1-C10 alkyl substituted with 0-3 R^{52} , and a heterocycle substituted with 0-3 R^{52} ;

R^{52} is independently selected at each occurrence from the group: a bond to L_n , =O, F, Cl, Br, I, -CF₃, -CN, -CO₂ R^{53} , -C(=O) R^{53} , -C(=O)N(R^{53})₂, -CHO, -CH₂OR⁵³, -OC(=O) R^{53} , -OC(=O)OR^{53a}, -OR⁵³, -OC(=O)N(R^{53})₂, -NR⁵³C(=O) R^{53} , -NR⁵⁴C(=O)OR^{53a}, -NR⁵³C(=O)N(R^{53})₂, -NR⁵⁴SO₂N(R^{53})₂, -NR⁵⁴SO₂R^{53a}, -SO₃H, -SO₂R^{53a}, -SR⁵³, -S(=O) R^{53a} , -SO₂N(R^{53})₂, -N(R^{53})₂, -NHC(=NH)NHR⁵³, -C(=NH)NHR⁵³, =NOR⁵³, NO₂, -C(=O)NHOR⁵³, -C(=O)NHN⁵³R^{53a}, -OCH₂CO₂H, 2-(1-morpholino)ethoxy;

R^{53} , R^{53a} , and R^{54} are each independently selected at each occurrence from the group: hydrogen, C1-C6 alkyl, and a bond to L_N ;

A_{L1} is a first ligand wherein each of the y first ligands are selected from the group consisting of: dioxygen ligands, functionalized aminocarboxylates, halides, and combinations thereof;

A_{L2} is a second ligand wherein each of the z second ligands are selected from the group consisting of: trisubstituted phosphines, trisubstituted arsines, tetrasubstituted diphosphines, tetrasubstituted diarsines, and combinations thereof;

x is independently 1-2;

y is independently 1-2; and


z is independently 0-4.

21. (previously added) The method of Claim 20 wherein M_T is selected from the group consisting of: technetium-99m, rhenium-186, and rhenium-188.

22. (previously added) The method of Claim 20 wherein the localization step comprises the step of localizing a compound of the formula (I) at the pulmonary embolus wherein Q is of the formula (II),

DOCKET NO.: DM6993/BMS-0689
Application No.: 09/534,893
Office Action Dated: April 11, 2003

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116



or a pharmaceutically acceptable salt or prodrug form thereof wherein:

R³¹ is a C₆-C₁₄ saturated, partially saturated, or aromatic carbocyclic ring system substituted with 0-4 R¹⁰ or R^{10a};

R³² is selected from:

- C(=O)-;
- C(=S)-
- S(=O)₂-;
- S(=O)-;
- P(=Z)(ZR¹³)-;

Z is S or O;

n" and n' are independently 0-2;

R¹ and R²² are independently selected from the following groups:

hydrogen,

C1-C8 alkyl substituted with 0-2 R¹¹;

C2-C8 alkenyl substituted with 0-2 R¹¹;

C2-C8 alkynyl substituted with 0-2 R¹¹;

C3-C10 cycloalkyl substituted with 0-2 R¹¹;

aryl substituted with 0-2 R¹²;

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, said heterocyclic ring being substituted with 0-2 R¹²;

=O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹³, -C(=O)R¹³, -C(=O)N(R¹³)₂, -CHO, -CH₂OR¹³, -OC(=O)R¹³, -OC(=O)OR^{13a}, -OR¹³, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³, -NR¹⁴C(=O)OR^{13a}, -NR¹³C(=O)N(R¹³)₂, -NR¹⁴SO₂N(R¹³)₂, -NR¹⁴SO₂R^{13a}, -SO₃H, -SO₂R^{13a}, -SR¹³, -S(=O)R^{13a}, -SO₂N(R¹³)₂, -N(R¹³)₂, -NHC(=NH)NHR¹³, -C(=NH)NHR¹³, =NOR¹³, NO₂, -C(=O)NHOR¹³, -C(=O)NHN(R¹³)R^{13a}, -OCH₂CO₂H, 2-(1-morpholino)ethoxy;

R¹ and R²¹ can alternatively join to form a 3-7 membered carbocyclic ring substituted with 0-2 R¹²;

when n' is 2, R¹ or R²¹ can alternatively be taken together with R¹ or R²¹ on an adjacent carbon atom to form a direct bond, thereby to form a double or triple bond between said carbon atoms;

R²² and R²³ can alternatively join to form a 3-7 membered carbocyclic ring substituted with 0-2 R¹²;

when n" is 2, R²² or R²³ can alternatively be taken together with R²² or R²³ on an adjacent carbon atom to form a direct bond, thereby to form a double or triple bond between the adjacent carbon atoms;

R¹ and R², where R²¹ is H, can alternatively join to form a 5-8 membered carbocyclic ring substituted with 0-2 R¹²;

R¹¹ is selected from one or more of the following:

=O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹³, -C(=O)R¹³, -C(=O)N(R¹³)₂, -CHO, -CH₂OR¹³, -OC(=O)R¹³, -OC(=O)OR^{13a}, -OR¹³, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³, -NR¹⁴C(=O)OR^{13a}, -NR¹³C(=O)N(R¹³)₂, -NR¹⁴SO₂N(R¹³)₂, -NR¹⁴SO₂R^{13a}, -SO₃H, -SO₂R^{13a}, -SR¹³, -S(=O)R^{13a}, -SO₂N(R¹³)₂, -N(R¹³)₂, -NHC(=NH)NHR¹³, -C(=NH)NHR¹³, =NOR¹³, NO₂, -C(=O)NHOR¹³, -C(=O)NHN(R¹³)R^{13a}, -OCH₂CO₂H, 2-(1-morpholino)ethoxy,

C1-C5 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C2-C6 alkoxyalkyl, C3-C6 cycloalkoxy, C1-C4 alkyl (alkyl being substituted with 1-5 groups selected independently from: $-NR^{13}R^{14}$, $-CF_3$, NO_2 , $-SO_2R^{13a}$, or $-S(=O)R^{13a}$),

aryl substituted with 0-2 R^{12} ,

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, said heterocyclic ring being substituted with 0-2 R^{12} ;

R^{12} is selected from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C5 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C5 alkoxy, $-CO_2R^{13}$, $-C(=O)NHOR^{13a}$, $-C(=O)NHN(R^{13})_2$, $=NOR^{13}$, $-B(R^{34})(R^{35})$, C3-C6 cycloalkoxy, $-OC(=O)R^{13}$, $-C(=O)R^{13}$, $-OC(=O)OR^{13a}$, $-OR^{13}$, $-(C1-C4\text{ alkyl})-OR^{13}$, $-N(R^{13})_2$, $-OC(=O)N(R^{13})_2$, $-NR^{13}C(=O)R^{13}$, $-NR^{13}C(=O)OR^{13a}$, $-NR^{13}C(=O)N(R^{13})_2$, $-NR^{13}SO_2N(R^{13})_2$, $-NR^{13}SO_2R^{13a}$, $-SO_3H$, $-SO_2R^{13a}$, $-S(=O)R^{13a}$, $-SR^{13}$, $-SO_2N(R^{13})_2$, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy, C1-C4 alkyl (alkyl being substituted with $-N(R^{13})_2$, $-CF_3$, NO_2 , or $-S(=O)R^{13a}$);

R^{13} is selected independently from: H, C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, $-(C1-C10\text{ alkyl})\text{aryl}$, or C3-C10 alkoxyalkyl;

R^{13a} is C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, -(C1-C10 alkyl)aryl, or C3-C10 alkoxyalkyl;

when two R¹³ groups are bonded to a single N, said R¹³ groups may alternatively be taken together to form -(CH₂)₂₋₅- or -(CH₂)O(CH₂)-

R¹⁴ is OH, H, C1-C4 alkyl, or benzyl;

R²¹ and R²³ are independently selected from:

hydrogen;

C1-C4 alkyl, optionally substituted with 1-6 halogen;
benzyl;

R² is H or C1-C8 alkyl;

R¹⁰ and R^{10a} are selected independently from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano,
C1-C5 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C5 alkoxy,
-CO₂R¹³, -C(=O)N(R¹³)₂, -C(=O)NHOR^{13a}, -C(=O)NHN(R¹³)₂, =NOR¹³,
-B(R³⁴)(R³⁵), C3-C6 cycloalkoxy, -OC(=O)R¹³, -C(=O)R¹³, -OC(=O)OR^{13a}, -OR¹³,

-(C1-C4 alkyl)-OR¹³, -N(R¹³)₂, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³, -NR¹³C(=O)OR^{13a},
-NR¹³C(=O)N(R¹³)₂, -NR¹³SO₂N(R¹³)₂, -NR¹³SO₂R^{13a}, -SO₃H, -SO₂R^{13a},
-S(=O)R^{13a}, -SR¹³, -SO₂N(R¹³)₂, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy,
C1-C4 haloalkyl (including -C_vF_w where v = 1 to 3 and w = 1 to (2v+1)), C1-C4
haloalkoxy, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino,
-OCH₂CO₂H, 2-(1-morpholino)ethoxy, C1-C4 alkyl (alkyl being substituted with -N(R¹³)₂,
-CF₃, NO₂, or -S(=O)R^{13a});

J is 3-aminopropionic acid or an L-isomer or D-isomer amino acid of structure

-N(R³)C(R⁴)(R⁵)C(=O)-, wherein:

R³ is H or C1-C8 alkyl;

R⁴ is H or C1-C3 alkyl;

R⁵ is selected from:

hydrogen;

C1-C8 alkyl substituted with 0-2 R¹¹;

C2-C8 alkenyl substituted with 0-2 R¹¹;

C2-C8 alkynyl substituted with 0-2 R¹¹;



C3-C10 cycloalkyl substituted with 0-2 R¹¹;

aryl substituted with 0-2 R¹²;

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently
selected from N, S, or O, said heterocyclic ring being substituted with 0-2 R¹²;

=O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹³, -C(=O)R¹³, -C(=O)N(R¹³)₂, -CHO,



-CH₂OR¹³, -OC(=O)R¹³, -OC(=O)OR^{13a}, -OR¹³, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³,
 -NR¹⁴C(=O)OR^{13a}, -NR¹³C(=O)N(R¹³)₂, -NR¹⁴SO₂N(R¹³)₂, -NR¹⁴SO₂R^{13a}, -SO₃H,
 -SO₂R^{13a}, -SR¹³, -S(=O)R^{13a}, -SO₂N(R¹³)₂, -N(R¹³)₂, -NHC(=NH)NHR¹³,
 -C(=NH)NHR¹³, =NOR¹³, NO₂, -C(=O)NHOR¹³, -C(=O)NHN(R¹³)R^{13a}, =NOR¹³,
 -B(R³⁴)(R³⁵), -OCH₂CO₂H, 2-(1-morpholino)ethoxy, -SC(=NH)NHR¹³, N₃, -Si(CH₃)₃,
 (C₁-C₅ alkyl)NHR¹⁶;
 -(C₀-C₆ alkyl)X;



-(CH₂)_mS(O)_{p'}(CH₂)₂X, where m = 1,2 and p' = 0-2;

and

R³ and R⁴ may also be taken together to form



R^3 and R^5 can alternatively be taken together to form $-(CH_2)_t-$ or $-CH_2S(O)p'C(CH_3)_2-$, where $t = 2-4$ and $p' = 0-2$; or

R^4 and R^5 can alternatively be taken together to form $-(CH_2)_u-$, where $u = 2-5$;

R^{16} is selected from:

an amine protecting group;

1-2 amino acids;

1-2 amino acids substituted with an amine protecting group;


K is a D-isomer or L-isomer amino acid of structure

$-(R^6)CH(R^7)C(=O)-$, wherein:

R^6 is H or C₁-C₈ alkyl;


R^7 is selected from:

$-(C_1-C_7 \text{ alkyl})X$;




, wherein each q is independently 0-2 and

substitution on the phenyl is at the 3 or 4 position;



, wherein each q is independently 0-2


and substitution on the cyclohexyl is at the 3 or 4 position;



-(CH₂)_mO-(C₁-C₄ alkyl)-X, where m = 1 or 2;

-(CH₂)_mS(O)_{p'}-(C₁-C₄ alkyl)-X, where m = 1 or 2 and p' = 0-2; and


X is selected from:




-N(R¹³)R¹³; -C(=NH)(NH₂); -SC(=NH)-NH₂; -NH-C(=NH)(NHCN);

-NH-C(=NCN)(NH₂); -NH-C(=N-OR¹³)(NH₂);

R⁶ and R⁷ can alternatively be taken together to form




n = 0 or 1 and X is -NH₂ or



L is -Y(CH₂)_vC(=O)-, wherein:

Y is NH, N(C1-C3 alkyl), O, or S; and v = 1 or 2;

M is a D-isomer or L-isomer amino acid of structure



q' is 0-2;

R¹⁷ is H, C1-C3 alkyl;

R⁸ is selected from:

-CO₂R¹³, -SO₃R¹³, -SO₂NHR¹⁴, -B(R³⁴)(R³⁵), -NHSO₂CF₃, -CONHNHSO₂CF₃,
-PO(OR¹³)₂, -PO(OR¹³)R¹³, -SO₂NH-heteroaryl (said heteroaryl being 5-10-membered
and having 1-4 heteroatoms selected independently from N, S, or O), -SO₂NH-heteroaryl
(said heteroaryl being 5-10-membered and having 1-4 heteroatoms selected independently
from N, S, or O), -SO₂NHCOR¹³, -CONHSO₂R^{13a}, -CH₂CONHSO₂R^{13a},
-NHSO₂NHCOR^{13a}, -NHCONHSO₂R^{13a}, -SO₂NHCONHR¹³;

R³⁴ and R³⁵ are independently selected from:

-OH,

-F,

-N(R¹³)₂, or

C1-C8-alkoxy;


R³⁴ and R³⁵ can alternatively be taken together form:

a cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-4 heteroatoms independently selected from N, S, or O;

a divalent cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-4 heteroatoms independently selected from N, S, or O;

a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-4 heteroatoms independently selected from N, S, or O.

23. (previously added) The method of Claim 22 wherein the localization step comprises the step of localizing a compound of the formula (I) at the pulmonary embolus wherein Q is of the formula (III),



or a pharmaceutically acceptable salt or prodrug form thereof wherein:

the shown phenyl ring may be further substituted with 0-3 R¹⁰;

R¹⁰ is selected independently from: H, C1-C8 alkyl, phenyl, halogen, or C1-C4 alkoxy;

R¹ is H, C1-C4 alkyl, phenyl, benzyl, or phenyl-(C1-C4)alkyl;

R² is H or methyl;

R¹³ is selected independently from: H, C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, -(C1-C10 alkyl)aryl, or C3-C10 alkoxyalkyl;

R^{13a} is C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, -(C1-C10 alkyl)aryl, or C3-C10 alkoxyalkyl;

when two R¹³ groups are bonded to a single N, said R¹³ groups may alternatively be taken together to form -(CH₂)₂₋₅- or -(CH₂)O(CH₂)-

R¹⁴ is OH, H, C1-C4 alkyl, or benzyl;

J is β-alanine or an L-isomer or D-isomer amino acid of structure -N(R³)C(R⁴)(R⁵)C(=O)-, wherein:

R³ is H or CH₃;

R⁴ is H or C1-C3 alkyl;

R^5 is H, C1-C8 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C1-C6 cycloalkylethyl, phenyl, phenylmethyl, CH_2OH , CH_2SH , CH_2OCH_3 , CH_2SCH_3 , $CH_2CH_2SCH_3$, $(CH_2)_sNH_2$, $-(CH_2)_sNHC(=NH)(NH_2)$, $-(CH_2)_sNHR^{16}$, where $s = 3-5$; or

R^{16} is selected from:

an amine protecting group;

1-2 amino acids; or

1-2 amino acids substituted with an amine protecting group;



R^3 and R^5 can alternatively be taken together to form $-CH_2CH_2CH_2-$; or

R^4 and R^5 can alternatively be taken together to form $-(CH_2)_u-$, where $u = 2-5$;


K is an L-isomer amino acid of structure $-N(R^6)CH(R^7)C(=O)-$, wherein:


R^6 is H or C1-C8 alkyl;

R^7 is:




$-(CH_2)_rX$, where $r = 3-6$;





-(CH₂)_mS(CH₂)₂X, where m = 1 or 2;

-(C₃-C₇ alkyl)-NH-(C₁-C₆ alkyl);




-(CH₂)_m-O-(C₁-C₄ alkyl)-NH-(C₁-C₆ alkyl), where m = 1 or 2;

-(CH₂)_m-S-(C₁-C₄ alkyl)-NH-(C₁-C₆ alkyl), where m = 1 or 2; and


X is -NH₂ or -NHC(=NH)(NH₂), provided that X is not -NH₂ when r = 4; or

R⁶ and R⁷ are alternatively be taken together to form



L is -Y(CH₂)_vC(=O)-, wherein:

Y is NH, O, or S; and v = 1,2;



M is a D-isomer or L-isomer amino acid of structure

wherein:


q' is 0-2;

R^{17} is H, C₁-C₃ alkyl;

R^8 is selected from:

-CO₂R¹³, -SO₃R¹³, -SO₂NHR¹⁴, -B(R³⁴)(R³⁵), -NHSO₂CF₃, -CONHNHSO₂CF₃,
 -PO(OR¹³)₂, -PO(OR¹³)R¹³, -SO₂NH-heteroaryl (said heteroaryl being 5-10-membered
 and having 1-4 heteroatoms selected independently from N, S, or O), -SO₂NH-heteroaryl
 (said heteroaryl being 5-10-membered and having 1-4 heteroatoms selected independently
 from N, S, or O), -SO₂NHCOR¹³, -CONHSO₂R^{13a}, -CH₂CONHSO₂R^{13a},
 -NHSO₂NHCOR^{13a}, -NHCONHSO₂R^{13a}, -SO₂NHCONHR¹³.

24. (previously added) The method of Claim 20 wherein the localization step
 comprises the step of localizing a compound of the formula (IV) at the pulmonary embolus:



(IV).

25. (canceled)

26. (canceled)

27. (previously added) The method of Claim 26 wherein the acquisition step comprises the step of acquiring single photon emission computed tomography images of the pulmonary embolus.

28. (previously added) The method of Claim 17 wherein the acquisition step comprises the step of acquiring transaxial image slices and further comprising the step of reformatting the transaxial image slices into image slices that are parallel to a long axis associated with the pulmonary embolus.

29. (previously added) The method of Claim 17 comprising the step of displaying the two dimensional array as a reprojected image.

30. (previously added) The method of Claim 17 wherein the scanning step is performed at a series of angles.

31. (previously added) The method of Claim 30 wherein the assignment step is performed at each of the series of angles.

32. (previously added) The method of Claim 31 comprising the step of sequentially displaying the two-dimensional arrays as reprojected images.

33-54. (canceled)

55. (previously added) The method of Claim 20 comprising the step of displaying the two-dimensional array as a reprojected image.

56. (previously added) The method of Claim 20 wherein the scanning step is performed at a series of angles.

57. (previously added) The method of Claim 56 wherein the assignment step is performed at each of the series of angles.

58. (previously added) The method of Claim 57 comprising the step of sequentially displaying the two-dimensional arrays as reprojected images.